(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/165181 A1

(51) International Patent Classification:
A61K 31/498 (2006.01) *A61P 35/04* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/EP2020/053490

(22) International Filing Date:
11 February 2020 (11.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
19156806.2 12 February 2019 (12.02.2019) EP
19176575.9 24 May 2019 (24.05.2019) EP

(71) Applicant: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **O'HAGAN, Anne Elizabeth**; c/o Janssen Pharmaceuticals Inc., Springhouse Campus 1400 McKean Road, Springhouse, Pennsylvania 19477 (US). **DE PORRE, Peter Marie Z.**; c/o: Janssen Pharmaceutica NV Turnhoutseweg 30, 2340 Beerse (BE). **AVADHANI, Anjali Narayan**; c/o: Janssen Pharmaceuticals Inc., Springhouse Campus 1400 McKean Road, Springhouse, Pennsylvania 19477 (US).

(74) Agent: **VERVOORT, Liesbeth**; Turnhoutseweg 30, 2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2020/165181 A1

(54) Title: CANCER TREATMENT

(57) Abstract: The present invention provides a method for the treatment of cancer with erdafitinib in high-risk patients.